Monopar Therapeutics Inc
NASDAQ:MNPR
Monopar Therapeutics Inc
Other Current Assets
Monopar Therapeutics Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Other Current Assets
$49.6k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-1%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$3.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$449.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
27%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$412m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
Monopar Therapeutics Inc
Glance View
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
See Also
What is Monopar Therapeutics Inc's Other Current Assets?
Other Current Assets
49.6k
USD
Based on the financial report for Sep 30, 2024, Monopar Therapeutics Inc's Other Current Assets amounts to 49.6k USD.
What is Monopar Therapeutics Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-39%
Over the last year, the Other Current Assets growth was -29%. The average annual Other Current Assets growth rates for Monopar Therapeutics Inc have been -23% over the past three years , -39% over the past five years .